Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 141.593 billion RMB for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 12.160 billion RMB, a decrease of 4.50% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 129.433 billion RMB, an increase of 2.17% year-on-year [1] Profit Analysis - The net profit attributable to shareholders was 4.459 billion RMB, representing a year-on-year increase of 51.56%, primarily due to a one-time special gain from changing the accounting treatment of a joint venture to a subsidiary [1] - Excluding one-time special gains and losses, the net profit attributable to shareholders was 2.782 billion RMB, showing a year-on-year decline of 2.06% [1] Strategic Focus - The company emphasizes steady progress and innovation, focusing on strengthening core competencies and enhancing development momentum through a "three horizontal and three vertical" development system [1] - Shanghai Pharmaceuticals has been recognized in the Fortune Global 500 and ranked 407th, while also being listed among the top 25 most valuable pharmaceutical brands globally, ranking 19th [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607) 截至2025年6月30日六個月未經審計中期業績公告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）欣然發佈本公司及其附屬公司 （合稱「本集團」）截至2025年6月30日六個月的中期業績。該中期業績乃根據中國企業會 計準則編製，未經審計。董事會及審計委員會已審閱並確認此中期業績。 本公司截至2025年6月30日六個月的中期報告全文附於本公告後。正式中期報告 將於適當時候在香港聯合交易所有限公司的網站(www.hkexnews.hk)和本公司網站 (www.sphchina.com)刊登。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年八月二十九日 於本公告日期，本公司的執行董事為楊秋華 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) reported a revenue of 141.593 billion yuan for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] - The company's net profit attributable to shareholders reached 4.459 billion yuan, marking a significant year-on-year increase of 51.56% [1] - However, the company's net profit excluding non-recurring items was 2.1 billion yuan, which represents a year-on-year decline of 22.38% [1] - Basic earnings per share stood at 1.20 yuan [1] Financial Performance - Revenue for the period was 141.593 billion yuan, up 1.56% year-on-year [1] - Net profit attributable to shareholders was 4.459 billion yuan, up 51.56% year-on-year [1] - Net profit excluding non-recurring items was 2.1 billion yuan, down 22.38% year-on-year [1] - Basic earnings per share were reported at 1.20 yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals announced a revenue of 141.593 billion yuan for the first half of 2025, representing a year-on-year growth of 1.56% [2] - The net profit attributable to shareholders reached 4.459 billion yuan, showing a significant year-on-year increase of 51.56% [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.1 billion yuan, reflecting a year-on-year decline of 22.38% [2] Financial Performance - Revenue for the first half of 2025: 141.593 billion yuan, up 1.56% year-on-year [2] - Net profit attributable to shareholders: 4.459 billion yuan, up 51.56% year-on-year [2] - Net profit after deducting non-recurring items: 2.1 billion yuan, down 22.38% year-on-year [2]

智通财经APP讯，上海医药(601607.SH)披露2025年半年度报告，报告期公司实现营收1415.93亿元，同 比增长1.56%;归母净利润44.59亿元，同比增长51.56%;扣非净利润21亿元，同比下降22.38%;基本每股收 益1.20元。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十四次會議決議公告》、《上海醫藥集 團股份有限公司關於上海上實集團財務有限公司2025半年度風險持續評估報告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 8 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文 ...

Core Viewpoint - Shanghai Pharmaceuticals has demonstrated a high-quality development characterized by "industrial quality improvement and stable commercial growth" in the first half of 2025, with a focus on strengthening core competencies and innovation breakthroughs [8] Financial Performance - The company achieved a revenue of 141.59 billion yuan, a year-on-year increase of 1.56%, with the pharmaceutical industry contributing 12.16 billion yuan and the pharmaceutical commerce segment contributing 129.43 billion yuan, which grew by 2.17% [1] - The net profit attributable to shareholders reached 4.46 billion yuan, reflecting a significant year-on-year growth of 51.56% [1] R&D and Innovation - R&D investment totaled 1.15 billion yuan, accounting for 9.44% of pharmaceutical industrial sales revenue, with 956 million yuan allocated specifically for R&D expenses [2] - The company has a pipeline of 56 new drugs, including 44 innovative drugs, with significant progress in clinical trials for various products [2] - The company is advancing its research platforms, achieving breakthroughs in personalized original candidate drug discovery [2] Strategic Collaborations and Ecosystem Development - The company is building an open-source innovation ecosystem, having completed the entry of eight high-growth enterprises into its Shanghai Biomedical Innovation Center [3] - A collaboration with Shanghai Jiao Tong University School of Medicine aims to establish a comprehensive service platform for early-stage technology transfer and validation [3] Industrial Transformation and Cost Management - The company is focusing on marketing transformation and lean management to enhance industrial business quality, reduce costs, and improve efficiency [4] - Cost savings of approximately 6.98 million yuan were achieved through centralized procurement, with an 8.6% reduction in costs [4] Traditional Chinese Medicine and New Retail Strategy - The company completed the acquisition of a 10% stake in Hehuang Pharmaceutical, which has shown growth in key performance indicators [5] - The company is enhancing its "big health OTC + new retail" strategy, achieving significant sales growth through innovative marketing channels [6] Commercial Innovation and Growth - The pharmaceutical commercial segment is leveraging technological innovation and digitalization, with notable growth in contract sales and import agency businesses [7] - The new retail strategy aims to create a patient-centered, integrated service model, enhancing service value and patient experience [7]

上海医药集团股份有限公司 关于上海上实集团财务有限公司 2025 半年度风险持续评估报 告 根据《上海证券交易所上市公司自律监管指引第 5 号——交易与关联交易》的 要求，上海医药集团股份有限公司（以下简称"上海医药"或"我们"）通过查验 上海上实集团财务有限公司（以下简称"财务公司"）的《金融许可证》、《营业 执照》等证件资料，审阅其二〇二五年度中期财务报表，对经营资质、业务和风险 状况进行了解和评估。具体情况报告如下： 一、 企业基本情况及经营资质 上海上实集团财务有限公司由上海上实（集团）有限公司（股东一）、上海医 药集团股份有限公司（股东二）、上海上实资产经营有限公司（股东三）以及上海 实业东滩投资开发（集团）有限公司（股东四）合资成立。2014 年 9 月 1 日在中华 人民共和国上海市注册成立的有限责任公司。 财务公司于 2014 年 8 月 26 日取得原中国银行业监督管理委员会上海监管局的 沪银监复、[2014]561 号开业批复，于 2014 年 9 月 1 日成立，注册资本人民币 10 亿元整，已于 2014 年 5 月 19 日全部缴入。财务公司取得上海市黄浦区市场监督管 理局颁发的营业 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-079 上海医药集团股份有限公司 第八届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届 董事会第二十四次会议（以下简称"本次会议"）于 2025 年 8 月 28 日在上海市 太仓路 200 号上海医药大厦 1101 会议室以现场结合通讯方式召开。本次会议应 到董事九名，实到董事九名，符合《中华人民共和国公司法》和本公司章程关于 董事会召开法定人数的规定。本次会议由杨秋华董事长主持，监事和部分高级管 理人员列席本次会议。 本议案已提交公司第八届董事会审计委员会第十三次会议审议通过，同意提 交董事会审议。 内容详见上海证券交易所网站 www.sse.com.cn。 表决结果：赞成 9 票，反对 0 票，弃权 0 票 2、《上海上实集团财务有限公司 2025 年半年度风险持续评估报告》 本议案已提交公司第八届董事会独立董事专门会议第十次会议 ...

Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a revenue of 141.593 billion yuan for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] - The net profit attributable to shareholders reached 4.459 billion yuan, marking a significant year-on-year increase of 51.56% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2.01 billion yuan, which represents a year-on-year decline of 22.38% [1] - The basic earnings per share stood at 1.20 yuan [1]